™E Pharma Announces Oral Presentation of NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma at ESMO Congress 2024 By Investing.com
BERLIN--(BUSINESS WIRE)--™E Pharma N.V. (Euronext Progress Paris: AL™E), a clinical-stage biotechnology firm targeted on growing novel therapies for remedy of ...